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Parkinson’s disease patients may be at increased risk of delirium and developing adverse 
outcomes, such as cognitive decline and increased mortality. Delirium is an acute state of 
confusion that has overlapping symptoms with Parkinson’s dementia, making it difficult to 
identify.  This study aimed to determine the diagnostic criteria, prevalence, management 
strategies and outcomes of delirium in Parkinson’s through a systematic review of the 
literature. 
Methods: 
Seven databases were used to identify all articles published before February 2017 
comprising two key terms: “Parkinson’s Disease” and “delirium”. Data were extracted from 
studies meeting predefined inclusion criteria. 
Results: 
Twenty articles were identified. Delirium prevalence in Parkinson’s ranged from 0.3-60% 
depending on setting; a diagnosis of Parkinson’s was associated with an increased risk of 
developing delirium. Delirium was identified/diagnosed using seven different criteria. 
Delirium may be associated with an increased length of hospital stay and worsening motor 
symptoms. We did not identify any studies examining the management of delirium in 
Parkinson’s.  
Discussion: 
This review highlights the paucity of well-designed, appropriately powered studies 
investigating delirium in Parkinson’s. The results suggest that delirium is a significant issue in 
people with Parkinson’s and that having delirium may be a risk factor for adverse outcomes, 
particularly in inpatient settings. Further prospective research is needed to accurately 
determine the prevalence of delirium in Parkinson’s, its management strategies and 
outcomes, and to evaluate diagnostic criteria to differentiate between the overlapping 




Parkinson’s disease (PD) is a neurodegenerative disorder defined by motor symptoms. 
However, it is now recognised that PD comprises a number of non-motor symptoms, which 
include neuropsychiatric features such as hallucination, delusions, anxiety and 
depression.[1] Cumulatively, 80% of patients with PD will develop dementia (PDD);[2] this is 
associated with chronic impaired but fluctuating attention, psychotic symptoms and 
delusions.[3] In addition, it is suspected that PD patients with and without dementia are at 
increased risk of delirium.[4] 
Delirium is an acute neuropsychiatric syndrome that is common in older adults admitted to 
hospital.[5] Delirium is associated with an altered level of consciousness, confusion and 
impaired attention.[6] Delirium can be distressing for both the person with delirium and 
their families. Delirium in older adults has been associated with both short term and long 
term adverse consequences, such as increased risk of falls, cognitive decline, nursing home 
placement and higher rates of death.[7, 8] Occurrence of delirium is also associated with 
prolonged hospital stay[9] and higher costs per patient per admission.[5] In the only 
population-based study exploring the impact of delirium on cognitive outcomes, delirium 
was associated with an eight-fold increased risk of future dementia.[10]  However, delirium 
may be preventable in a third of cases.[11, 12] Therefore, early detection and diagnosis 
could lead to improved outcomes for patients and reduced hospital costs.  
There may be an overlapping clinical phenotype of PD and delirium. Commonly reported PD 
symptoms, such as attentional dysfunction, cognitive fluctuations, hallucinations, sleep 
disturbance and daytime somnolence are also common in delirium,[4, 6] making it difficult 
to distinguish PD symptoms from delirium. Therefore, previous studies may have either 
underestimated or overestimated the prevalence of delirium in people with PD. 
Additionally, the management of delirium in PD is complex. Dopaminergic medication may 
predispose to delirium; neuroleptic medication, often used to treat delirium in older adults, 
may worsen motor symptoms resulting in increased rigidity and bradykinesia, which in turn 
can cause falls, impaired swallowing, aspiration and dehydration. 
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Patients with PD may be at increased risk of developing delirium and adverse outcomes. 
Understanding the relationship between delirium and PD could help guide clinical practice. 
The aim of this systematic review was to: i) determine how delirium has been 
defined/diagnosed in PD patients in previous studies, ii) describe common presentations of 
delirium in people with PD, iii)  establish the therapeutic strategies used to manage delirium 
in PD, and iv) determine the outcomes of delirium in people with PD. 
Methods 
Search strategy 
We searched seven databases: Medline, Embase, PsychINFO, Cochran, Scopus, Web of 
Knowledge and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). The 
search comprised two key terms: “Parkinson’s Disease” and “delirium”. For each key term, a 
list of synonyms were compiled (Table 1); where available, MeSH terms were used. The 
search included all articles published before February 2017. In addition, we examined 
references of articles from the search for articles not identified in the searches, but may be 
suitable for inclusion. 
A central database was compiled using articles from the search; RAL removed all duplicates. 
Reviewers (RAL and CM) reviewed the titles and abstracts independently. The full text was 
reviewed where it was unclear whether the paper met inclusion criteria. 
Inclusion and exclusion criteria 
Articles were included if PD and delirium were referred to in the title or abstract, the paper 
was written in English and the full text was available. Articles were excluded if they included 
subjects with non-idiopathic parkinsonism, including multiple system atrophy, progressive 
supranuclear palsy, dementia with Lewy bodies (DLB), vascular PD, drug induced PD, 
subjects with a diagnosis of PD for less than one year, and could therefore meet the criteria 
for DLB, or where subjects had a history of brain injury or brain tumour. Review articles and 




A data extraction form was generated which included study setting, study population, how 
participants were selected/identified, duration of study and follow up period. Key outcomes 
were also included on the data extraction form, including how delirium was diagnosed, the 
prevalence of delirium in PD, presenting symptoms of delirium, how delirium was managed 
and clinical outcomes associated with delirium, for example, duration of hospital admission, 
change in motor symptoms or cognitive function and mortality. 
Results 
The database searches identified 5672 potentially relevant articles ( Figure 1). After 
duplicates were removed (n=1278), 4394 articles were identified. The title and abstract of 
the potentially relevant articles were screened and 4337 were excluded. We reviewed the 
full text of the remaining 56 articles. Thirty-nine articles were excluded because: the full text 
was not available in English (n=4), they were a conference abstract and no full text was 
available (n=19), the key outcomes identified by this systematic review were not available 
from the papers (n=15), or the paper was a systematic review (n=1). In addition to the 17 
papers identified in the search which met inclusion criteria, three additional papers were 
identified by reviewers [13-15] by reviewing references of articles from the search and a 
previous review,[4] yielding a total of 20 papers which were eligible for data extraction 
(Table 2). 
Characteristics of studies and participants 
Of the 20 studies identified, ten were prospective, nine were retrospective and one was a 
case-control study (Table 2). The majority of studies were in an inpatient setting (n=17) with 
two studies conducted in outpatients[16, 17] and one in residential and nursing homes.[18]  
The samples ranged in size from 15-182,859 subjects with PD.[14, 19] The largest studies 
were retrospective review of medical databases.[14, 20, 21] Older adults were the focus of 
the research in three studies, of which a proportion of subjects had PD.[18, 22, 23] Eight 
studies included postoperative subjects with PD (Table 2), five of which included PD patients 
who had undergone deep brain stimulation (DBS) surgery.[13, 19, 24-26] 
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Participants with PDD were included in eight studies[14, 15, 18, 20, 22, 23, 27, 28] but were 
excluded from seven (Table 2).[13, 24-26, 29-31] The remaining studies did not give explicit 
details as to whether PDD participants were included in the study.[16, 17, 19, 21, 32] 
Defining and diagnosing delirium 
The criteria used to diagnose or identify delirium varied between studies (Table 2). Three 
studies used validated diagnostic criteria to diagnose delirium (Table 3). These comprised 
the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)[16, 28] and the 
International Classification of Diseases 10th Revision (ICD-10).[14] Three studies used the 
Confusion Assessment Method (CAM), a validated assessment tool designed to allow non-
specialists to identify delirium.[22, 30, 31] In addition, Boorsma, et al. [18] used an adjusted 
version of the Nursing Home-CAM retrospectively by matching data from the Resident 
Assessment Instrument, a database used in Dutch nursing and residential care. However, 
the papers did not specify  how these criteria were applied and what methods were used to 
assess specific criteria, such as attention. 
The definition of delirium varied more widely between the remaining studies. Delirium was 
diagnosed by expert opinion by Golden, et al. [29] and  Woodford and Walker.[15] Broader 
definitions of delirium were employed, which comprised  “transient post-operative 
confusion”[19] and any event of hallucinations, delusions, or disorientation to 
circumstance.[24] Lange, et al. [25] defined delirium as “an altered mental state of reduced 
cooperation due to fear, psychomotor agitation and impaired or lost orientation.” Oichi, et 
al. [21] used the prescription of antiparkinsonian medication as a marker for PD, and 
classified patients as having delirium if they were newly prescribed antipsychotic drugs 
postoperatively, which included quetiapine, risperidone, trazodone, mianserin and 
haloperidol. Six studies did not explicitly state how delirium was defined or diagnosed.[13, 
17, 20, 26, 27, 32] 
Prevalence of delirium 
The prevalence of delirium varied between studies and ranged from 0.3-60% (Table 2). This 
likely reflects the variation in study design including setting, patient populations and 
definitions of delirium used across studies. Studies reporting primary and secondary reasons 
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for hospital admissions reported the lowest prevalence rates (0.3-5%).[14, 15] This method 
most likely underestimates the prevalence of delirium. Delirium is frequently secondary to 
an acute illness such as infections or hip fractures. The acute illness triggering delirium is 
more likely to be reported as the reason for admission rather than the concurrent delirium. 
This is demonstrated by the higher rates of delirium reported among medical inpatients. 
Studies that prospectively reviewed patients to identify delirium or retrospectively reviewed 
case notes for evidence of delirium reported prevalence of 22-48%. Similarly, studies that 
assessed the prevalence of delirium in PD patients undergoing surgery reported prevalence 
rates of 11-60% in PD subjects (Table 2).[13, 19, 22, 24-26, 29] The prevalence of delirium 
was lower in patients undergoing DBS (11-27%) compared to other surgeries (22-60%). 
Delirium prevalence in outpatient settings was lower at 4%.[16, 17] This likely reflects a 
population among which acute undercurrent illness was less common.  
The prevalence was unclear in some studies due to the indistinct definitions of delirium 
applied.[20, 27] The prevalence of delirium in PD could not be ascertained by two 
studies,[22, 31] although Oh, et al. [22] reported that having PD was associated with a 
threefold increased risk of developing delirium (Table 2). Three other studies suggested 
having PD was associated with an increased risk of delirium.[18, 20, 21] Subjects with PD 
were five times as likely to be treated for delirium in inpatient settings,[20] and residents in 
a nursing home with PD were more than twice as likely to suffer from delirium. 
Postoperatively, Oichi, et al. [21] found delirium was 8 times more likely in patients with PD 
undergoing spinal surgery than patients without PD undergoing the same surgery. 
Symptoms of delirium 
Eleven studies presented findings pertaining to symptoms of delirium in PD subjects.[16, 17, 
19, 24-26, 28-32] Confusion and disorientation were the most commonly reported 
symptoms of delirium.[19, 25, 29, 31, 32]. Hallucinations and/or delusions were also 
commonly reported symptoms,[16, 17, 24, 29] although the two symptoms were not 
necessarily differentiated between. Golden, et al. [29] reported hallucinations in 36% of PD 
participants following DBS. Hallucinations were reported in all PD subjects with delirium by 
Nishikawa, et al. [17], but it was not clear whether hallucinations were directly related to 
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delirium. Disturbances and fluctuations in consciousness, cognition and perception were 
symptoms associated with delirium.[28, 29] Golden, et al. [29] was the only study which 
reported day-night reversal although this was only in one subject. However, studies did not 
systematically assess or report these symptoms, thus it was not possible to draw 
conclusions as to their frequency. 
Three studies hinted at delirium phenotype. Serrano-Duenas and Bleda [31] identified 76% 
of PD subjects with delirium as “agitated type” delirium, while Lange, et al. [25] and 
Schupbach, et al. [26] reported that a small proportion of subjects (n=5 and n=3, 
respectively) had postoperative hypomania. However, this should be viewed with caution, 
as hyperactive delirium was not explicitly stated. Of the remaining studies, a description of 
symptoms of delirium were either unclear or not stated. 
Outcomes of delirium 
Accurately defining the outcomes of delirium in patients with PD is challenging due to the 
limited information available from only nine studies (Table 2).[17, 24, 25, 27-32] Duration of 
delirium in PD patients ranged from 24 hours or less, to under 30 days.[17, 25, 29] Two 
studies showed that delirium was associated with extended hospital stay compared to PD 
patients without delirium.[24, 27] 
Longitudinal studies suggested that delirium could be associated with a worsening of motor 
symptoms in PD patients.[28, 31] Umemura, et al. [28] showed that patients with delirium 
were more than 15 times more likely to have motor deterioration (OR=15.9), while Serrano-
Duenas and Bleda [31] showed that subjects with PD and delirium had significantly poorer 
motor scores compared to PD subjects without delirium after five years. Gerlach, et al. [32] 
reported that patient complications while hospitalised, which included delirium, were 
associated with a decline in motor symptoms,  but the contribution of delirium could not be 
determined. 
Whether delirium was associated with future PDD could not be ascertained. Serrano-Duenas 
and Bleda [31] found delirium was significantly associated with a decline in cognitive 
function over five years and increased mortality rates  compared to age-matched PD 
patients without delirium and controls. However, these results should be viewed with 
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caution due to the small sample size used (21 PD, 21 PD with delirium and 21 controls), and 
does not take into account additional hospital admissions or episodes of delirium. In 
addition, none of the studies assessed interventions for delirium or its associated outcomes.  
Discussion 
Key findings of this review include that the prevalence of delirium in PD varied widely 
between studies and settings, ranging from 0.3% to 60% of subjects, as did the criteria used 
to identify or diagnose delirium. In inpatient settings, delirium occurred in 11-60% patients 
and overall having PD was associated with an increased risk of developing delirium. Findings 
relating to symptoms and outcomes of delirium in PD patients were limited, but delirium 
may be associated with increased length of hospital stay and worsening motor symptoms. 
The results showed that up to 60% of PD inpatients have delirium, and that having PD was a 
risk factor for developing delirium.[18, 20-22] However, given the wide range of reported 
prevalence of delirium in PD, some caution should be made when interpreting these results. 
The variation likely reflects the heterogeneous samples, settings and criteria used to define 
delirium in PD subjects. Firstly, the sample and study setting varied across studies and 
included both large retrospective studies and smaller prospective studies. As expected, 
delirium prevalence was lower in outpatient settings (4%) compared to inpatient settings 
(22-48%) and postoperatively (11-60%). The proportion of PD patients whose primary 
reason for admission to hospital was delirium was low (0.3-5%). This likely reflects current 
coding practices, where the underlying condition leading to delirium is documented as the 
primary reason for admission; however, this underestimates the proportion of patients 
whose admission is complicated by delirium.  It also does not reflect cases were delirium 
developed while in hospital.[24]. 
A number of studies excluded patients with PDD; PDD is common and develops in up to 80% 
of patients.[2] As people with PDD may be most at risk of delirium,[18] a key group of 
people are likely to have been under investigated in previous research. None of the studies 
stratified for dementia; it is therefore difficult to determine the extent to which PDD or PD 
alone is a risk factor for delirium. Vida, et al. [23] showed that in non-demented older 
adults, participants with delirium had poorer instrumental activities of daily living (ADL) 
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after 18 months compared to those without delirium, but there was no difference in 
functional outcomes in demented participants. This may reflect the pre-existing impact of 
dementia on ADL. 
Nine different criteria were to used identify or diagnose delirium, and in six studies no 
methods were stated. Only seven studies used existing diagnostic criteria or a validated 
diagnostic tool to identify delirium in PD. Other studies used broader definitions of delirium, 
which included symptoms such as confusion or presence of hallucinations. Only a few 
studies referred to fluctuating cognition, but it was not clear whether this was a feature of 
cognitive impairment associated with PD or delirium. Use of objective measures, such as 
repeated cognitive tests, e.g. the Mini Mental State Examination, to determine change in 
cognition or improvement over time were not reported in the articles. Finally, the validity of 
the assessment tools, such as CAM, used by non-specialists to identify delirium have not 
been validated in PD. These issues have the potential to misidentify delirium as these 
symptoms are not uncommon in PD,[3] and several articles were unclear whether these 
were acute changes or longstanding symptoms associated with PD.  
Only limited inference could be made about the repercussions of delirium in PD patients. 
Increased length of hospital stay was associated with delirium in PD in two studies. This is 
consistent with studies in older adults, where occurrence of delirium has also been 
associated with prolonged hospital admission[9] and higher costs per patient per 
admission.[5] However, duration of hospital admission can be influenced by other factors, 
such as comorbidities and frailty, which are also risk factors for delirium. 
An increasing number of studies have reported that delirium is a predictor of dementia and 
is associated with worsening of existing cognitive decline.[10, 33-35] Only one study has 
examined the association between delirium and cognitive decline in PD. Serrano-Duenas 
and Bleda [31] found that PD patients with delirium were at greater risk of cognitive decline 
five years later. This is in keeping with studies in the general population. A population-based 
study in older adults found that delirium was associated with an eight-fold increased risk of 
future dementia.[10] A systematic review in older adults reported that delirium was 
associated with increased mortality, functional outcomes and institutionalisation.[9] Further 
research replicating these findings in PD patients is needed. 
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There are some limitations to be acknowledged. We used a broad search strategy but 
excluded articles not available in English; however, we believe this review is comprehensive 
and includes the key findings in this area. The quality and methodological rigour differed 
between studies. Although some studies used the Queen’s Square Brain Bank criteria to 
identify idiopathic PD, this was not always possible due to the methodology of some studies, 
for example in retrospective studies. One study used prescribed anti-parkinsonian 
medication as a surrogate marker for PD,[21] however, this could inadvertently include 
patients with other parkinsonian conditions and patients who used dopaminergic therapy, 
for other indications such as restless legs syndrome. Retrospective studies of hospital 
databases and review of medical notes has the advantage of accessing large amounts of 
existing data. However, it has been shown that medical records are unreliable sources of 
delirium as delirium is under-diagnosed, inconsistently documented and under-
reported.[36] Furthermore, as demonstrated in one paper,[20] delirium and 
encephalopathy can be used interchangeably; therefore, delirium could be misreported in 
some subjects. Due to the limited number of studies whose focus was delirium in PD, we 
used broad criteria to identify and consolidate all currently published literature in this area. 
However, our findings highlights the need of future studies to use validated criteria to verify 
the diagnosis of idiopathic PD, such as the Queen’s Square Brain Bank criteria, and delirium, 
such as DSM-5 criteria or CAM. 
Most noticeably, we did not find any studies examining interventions to prevent or treat 
delirium in PD. The dopaminergic and cholinergic deficits in PD theoretically make patients 
more vulnerable to delirium and it remains to be established if conservative measures 
shown to prevent delirium in general older adults are as effective in PD.[11, 12] 
Furthermore, there are specific challenges to managing delirium in PD. Many of the 
medications prescribed to PD patients are associated with increased risk of delirium, and 
guidelines suggest a medication review should form part of the management of delirium in 
PD.[37]  
A first approach should be to identify and treat the underlying precipitant (e.g. infection, 
dehydration etc.). Where conservative measures and treating the underlying precipitant 
fails, clinicians may be required to alter or suspend PD medication. The consensus is that 
drugs with the greatest anticholinergic effect should be removed first.[4] Thus, PD 
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medication could be stopped or suspended in the following order: anticholinergics, 
amantadine, monoamine oxidase inhibitors, dopamine agonists, levodopa. A review of the 
current evidence, however, shows these guidelines are not based on hard evidence but 
clinical experience.[4] It must be noted that the sudden withdrawal of dopaminergic 
medication could increase the risk of patients developing delirium. 
Antipsychotic medications are used in patients without PD to control delirium; however, a 
meta-analysis of randomised controlled trials (RCTs) failed to show any impact of 
antipsychotics on duration or severity of delirium, or on length of stay or mortality.[38] 
Most antipsychotics can worsen motor symptoms in PD and are, therefore, relatively 
contraindicated. Where neuroleptic mediation is necessary, quetiapine is considered the 
safest choice; however, there are no studies examining its use in PD.[4] Other agents have 
been considered for delirium, but not specifically in PD. RCTs of cholinesterase inhibitors in 
older adults have failed to show superiority compared to placebo, and some have suggested 
increased adverse events in the treatment arm of these studies.[39] Melatonin has been 
associated with a decreased incidence of delirium in RCTs performed in older patients on 
medical wards, but not in the surgical setting.[40]  
In summary, this review highlights that there is a paucity of well-powered studies 
investigating delirium in PD and its outcomes. Nonetheless, the results suggest that delirium 
is a significant issue in people with PD; it may occur more frequently in PD than in older 
adults, particularly in inpatient settings and postoperatively. Given its potential association 
with worsening PD motor symptoms, cognitive decline and increased mortality rates, it is 
important that delirium is regularly screened for and its diagnosis recorded appropriately. 
More research is warranted in this area. We propose that future studies should consider 
using prospective methods to investigate the prevalence of delirium in PD, its outcomes and 
management strategies. Studies that accurately characterise delirium in PD and evaluate 
diagnostic criteria may also be useful to clinicians and researchers to differentiate between 
the overlapping symptoms of PD and delirium. A better understanding of delirium and its 
presentation in PD will be important for treatment selection in future clinical trials to treat 
or prevent delirium. 
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